Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glomerulonephritis, Membranous Clear all
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn Phase 4 Interventional

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

NCT01926054
View directory record Official record
Conditions
SLE Glomerulonephritis Syndrome, WHO Class V
Interventions
Acthar gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

NCT07516964
View directory record Official record
Conditions
Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Interventions
Serum and renal tissue analysis
Other
Lead sponsor
Meyer Children's Hospital IRCCS
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

NCT00977977
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Interventions
Rituximab Infusion, Oral Cyclosporine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 4 Interventional Results available

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

NCT01129557
View directory record Official record
Conditions
Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

Atacicept in Multiple Glomerular Diseases

NCT06983028
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Povetacicept, Tacrolimus
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

NCT04278729
View directory record Official record
Conditions
Nephrotic Syndrome, Membranous Nephropathy
Interventions
Apixaban 5 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT07571746
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

NCT04145440
View directory record Official record
Conditions
Glomerulonephritis, Membranous, antiPLA2R Positive
Interventions
MOR202
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Azusa, California • San Francisco, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 1Phase 2 Interventional

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

NCT04652570
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
VB119
Drug
Lead sponsor
Tenet Medicines
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Albany, New York • Bethlehem, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

NCT01129284
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

NEPTUNE Match Study

NCT04571658
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT06557265
View directory record Official record
Conditions
Lupus Nephritis, Primary Membranous Nephropathy
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Tustin, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Early Phase 1 Interventional

Rituximab in the Treatment of Idiopathic Membranous Nephropathy

NCT00405340
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn Not applicable Interventional

Aliskiren in Patients With Idiopathic Membranous Nephropathy

NCT01093781
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
Aliskiren
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852
View directory record Official record
Conditions
Glomerulonephritis, Membranous
Interventions
Belimumab 10 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

NCT05707377
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Zanubrutinib, Tacrolimus
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

MEmbranous Nephropathy Trial Of Rituximab

NCT01180036
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
Rituximab, Cyclosporine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Sep 30, 2026, 9:08 AM EDT